Unfortunately, the phase III trial in melanoma patients (ECHO- 301/KEYNOTE-252) failed in confirming efficacy of epacadostat and pembrolizumab combination [18], leaving open question on the clinical relevance of Ido-1 inhibition in cancer treatment. Here, IDO1 is linked to melanoma.